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Objectives: The purpose of this study was to investigate the seroprevalence of
hepatitis A virus (HAV) and hepatitis E virus (HEV) in Korea during 2005.
Methods: Study subjects were selected from across Korea using a stratified
multistage probability sampling design, and HAV and HEV seroprevalence was
compared on the basis of sex, age, and residency. A total of 497 rural and urban
people aged 10e99 years of age (mean  SD age Z 28.87  17.63 years) were
selected by two-stage cluster sampling and tested serologically for anti-HAV and
anti-HEV IgG using an enzyme-linked immunosorbent assay.
Results: Among this population, the overall seroprevalence of HAV was 63.80%
(55.21% aged in their 20s and 95.92% in their 30s, p < 0.01) and that of HEV was
9.40% (5.21% aged in their 20s and 7.14% in their 30s, p < 0.01). Seroprevalence
also varied according to area of residence. HEV prevalence in rural areas was
higher than that of urban regions based on the anti-HEV antibody, odds ratio 3.22
(95% confidence interval: 1.46e7.10, p < 0.01). There were no significant
differences between male and female against anti-HAV/HEV antibodies.
Conclusion: Our study suggested that the seropositive rates of HAV and HEV
might be related to age and environmental conditions.ibuted under the terms of the Creative Commons Attribution Non-Commercial License
y-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in
is properly cited.
ol and Prevention. Published by Elsevier. All rights reserved.
A seroprevalence study of hepatitis A and E viruses in Korea 471. Introduction
Hepatitis A (HAV) and E (HEV) viruses have
a global distribution and are transmitted by means of the
oral-fecal route by the consumption of contaminated
water. Human isolates of HAV are classified only as
a single serotype. However, previous studies have
indicated that significant nucleic acid heterogeneity
exists within isolates, allowing them to be grouped
according to geographical origin. HEV-mediated hepa-
titis is a serious public health problem in the developing
countries of Asia, the Middle East, Africa, and Central
America [1e3]. The highest incidence of HEV infection
occurs in young adults, whereas high rates of fulminant
disease are also associated with pregnancy. Waterborne
epidemics of this disease have been reported in South-
east and Central Asia, the Middle East, Africa, and
North America [4]. Most HEV infections reported in
developed countries were identified in travelers who had
previously visited HEV endemic countries.
Worldwide epidemiological patterns (low, interme-
diate, and high) of endemicity are dependent on the age
of individuals and hygiene levels [5e7]. Even within
a designated country, patterns of infection are variable
based on the rate of infection, prevalent age, of a pop-
ulation and modes of transmission [8]. Although sero-
prevalence is low during childhood in industrialized
countries with low endemicity pattern, the age group of
the most susceptible population has changed from young
children to older children and adults [9] (WHO 2000,
WHO/CDS/CSR/EDC/2000-7). Clinically severe cases
of HAV infection in non-immune adults have also
increased recently.
In developing countries, low economic status, high
crowding, and inadequate water treatment contribute to
a high endemicity pattern, with more than 90% of the
population having acquired natural immunity before 10
years of age and infection often persisting as asymp-
tomatic forms [8,10]. With the implementation of
improved standards of hygiene, sanitation, and socio-
economic conditions, the epidemiologic pattern of hepa-
titis A infection and other infectious diseases is currently
changing in many developing countries [7,11,12]. Studies
conducted in such emerging countries have reported
epidemiologic changes over the last decade. HAV and
HEV now appear to affect the population at a later age,
with an increased risk of symptomatic infection and
potentially more severe forms of this disease [13].
In Korea, epidemiologic-serological prevalence data
on HAV and HEV transmitted by means of oral-fecal
route are fragmentary, non-systematic and limited to
studies on acute symptomatic HAV infection [14e16].
The purpose of this study was to investigate the age-
specific epidemiological characteristics of HAV and
HEV serology in Korea based on the third National
Health and Nutrition Survey.2. Materials and Methods
2.1. Study design and population
This study was a descriptive, cross-sectional, seroe-
pidemiological investigation of HAV and HEV among
497 people from Korea, who were aged between 10 and
99 (mean age 29.01 years). People were selected from
across Korea using a stratified multistage probability
sampling design, and constituted a representative
sample of the Korean population. The Ethics Committee
of the Korea National Institute of Health approved both
the study protocol and the statement of informed consent
of the third Korea National Health and Nutrition Survey
III. Written informed consent was also obtained from all
subjects before the start of this study. Our study was
conducted between 1 April 2005 and 31 June 2005, in
accordance with the Declaration of Helsinki and Good
Clinical Practice guidelines in force during this time.
2.2. Data collection method
Data collected included general information on
participants (sex, age, and residency), who were cate-
gorized into six age groups that ranged from 10 to 99
years old. After informed consent was obtained from
participants or parents in the case of individuals who
were under 16 years old, blood samples were collected
for HAV and HEV serology.
2.3. Enzyme-linked immunosorbent assay
To assess seroprevalence, the presence of anti-HAV
IgG in human sera was determined using a commercial
HAV enzyme-linked immunosorbent assay (ELISA) kit
according to the manufacturer’s instructions (Diagnostic
Automation Inc., Calabasas, CA, USA). Briefly, 50 mL
of each test serum sample, and positive and negative
controls, were added to the microplate. Horseradish
peroxidase-conjugate antibody (50 mL) was then added
to each well, except the blank, and the microplate was
incubated for 1 hour at 37C. The microplate was then
washed before chromogen solution A and TMB were
added. The color-developing reaction was stopped and
the absorbance for each well was determined at 450 nm
with a Sunrise microplate reader (TECAN Trading AG,
Ma¨nnedorf, Switzerland).
The presence of anti-HEV IgG in human sera was
determined using a commercial HEV ELISA kit
according to the manufacturer’s instructions (Diagnostic
Automation, Inc.). Briefly, 10 mL of the serum sample
was added to each well containing 100 mL of the diluent,
and the microplate was incubated for 30 minutes at
37C. The microplate was washed before Horseradish
peroxidase-conjugated HEV antigen was added. The
microplate was further washed and then chromogen
solution and TMB were added. The color-developing
reaction was stopped and the absorbance was deter-
mined as described above.
Table 1. Seroprevalence of anti-HAV antibodies in Korea according to sex, age, and residency
Variables Total number (%) Number of anti-HAV IgG positives (%) Odds ratio (95% CI)a p
Sex
Male 239 (48.88) 145 (60.67) 1 0.1585
Female 250 (51.12) 167 (66.80) 1.30 (0.90, 1.89)
Age groups
10e14 118 (24.13) 45 (38.14) 1 <0.0001
15e19 78 (15.95) 22 (28.21) 0.64 (0.34, 1.18)
20e29 96 (19.63) 53 (55.21) 2.00 (1.16, 3.46)
30e39 98 (20.04) 94 (95.92) 38.12 (13.11, 110.85)
40e59 65 (13.29) 65 (100.00) 55.00 (22.10, 115.70)
60 34 (6.95) 33 (97.06) 53.53 (7.07, 405.10)
Residency
Urban 201 (41.10) 124 (61.69) 1 0.6183
Suburban 234 (47.85) 151 (64.53) 1.13 (0.76, 1.67)
Rural 54 (11.04) 37 (68.52) 1.35 (0.71, 2.57)
aCI Z confidence interval; 1 Z referent.
Odds ratio to have HAV antibioses by sex, age group and residency calculated by c2 test. HAV Z hepatitis A virus.
48 H. Yun, et al2.4. Statistical analysis
We compared the seropositivity of HAV and HEV on
the basis of sex, age, and residency by administrative
district (urban; suburban; rural). Each of these variables
was selected as a possible risk factor based on previous
studies. If required, c2 and Cochran-Mantel-Haenszel
(CMH) tests were performed. The level of significance
was p < 0.05 and all statistical analyses were performed
using SAS version 8.0 (SAS Institute Inc., NC, USA).3. Results
The overall prevalence of HAV was 63.80%, with
60.67% (n Z 145) of infections in males and 66.80%
(n Z 167) in females. According to age group,
a significant increase in prevalence was observed with
increasing age. For individuals in their 20s, 30s, and 40s,Table 2. Seroprevalence of anti-HEV antibodies in Korea acco
Variables Total number (%) Number of anti-HEV I
Sex
Male 239 (48.88) 26 (10.8
Female 250 (51.12) 20 (8.00
Age groups
10e14 118 (24.13) 1 (0.85
15e19 78 (15.95) 0 (0.00
20e29 96 (19.63) 5 (5.21
30e39 98 (20.04) 7 (7.14
40e59 65 (13.29) 15 (23.0
60 34 (6.95) 18 (52.9
Residency
Urban 201 (41.10) 18 (8.96
Suburban 234 (47.85) 15 (6.41
Rural 54 (11.04) 13 (24.0
aCI Z confidence interval; 1 Z referent.
Odds ratio to have HEV antibioses by sex, age group and residency Calculateda prevalence of 55.21% (nZ 53), 95.92% (nZ 94) and
100% (n Z 65) was observed, respectively, compared
with that in the 10e14 age group (p < 0.01). There were
no differences in prevalence based on residency (Table 1).
The overall prevalence of HEV was 9.40%, with 10.88%
(n Z 26) in males and 8% (n Z 20) in females. For
individuals in their 20s, 30s and 40s, a prevalence of
5.21% (nZ 5), 7.14% (nZ 7), and 23.08% (nZ 15) was
observed, compared with that in the 10e14 age group
(p < 0.01). Prevalence in people from rural areas was
significantly higher than that in people from urban areas
(pZ 0.01) (Table 2).
Based on statistical analysis, no significant difference
in overall HAV prevalence was observed between males
and females. However, on the basis of age, significant
differences were observed between the 31.25% (among
individuals in their 10s), 46.81% (20s), 95.92% (30s),
and 100% (40s) prevalence rates for males (p < 0.01).rding to sex, age, and residency
gG positives (%) Odds ratio (95% CI)a p
8) 1 0.2757




) 9.00 (1.09, 74.47)
8) 35.10 (4.51, 272.97)
4) 131.63 (16.44, 148.07)
) 1 0.0003
) 0.70 (0.34, 1.42)
7) 3.22 (1.46, 7.10)
by c2 test. HEV Z hepatitis E virus.
Table 3. Seroprevalence of antibodies against HAV/HEV in Korea according to age and sex
Age groups
Percent positives (number of anti-HAV
IgG positive/total number)
Percent positives (number of anti-HEV
IgG positive/total number)
Male* Female* Male* Female*
10e14 35.19 (19/54) 40.63 (26/64) 1.85 (1/54) 0.00 (0/64)
15e19 2.16 (11/42) 30.56 (11/36) 0.00 (0/42) 0.00 (0/36)
20e29 46.81 (22/47) 63.27 (31/49) 4.26 (2/47) 6.12 (3/49)
30e39 95.92 (47/49) 95.92 (47/49) 8.16 (4/49) 6.12 (3/49)
40e59 100.00 (32/32) 100.00 (33/33) 31.25 (10/32) 15.15 (5/33)
60 93.33 (14/15) 100.00 (19/19) 60.0 (9/15) 47.37 (9/19)
Total 60.67 (145/239) 66.80 (167/250) 10.88 (26/239) 8.00 (20/250)
*A p value <0.0001 by c2 test. Calculated by Cochran-Mantel-Haenszel Statistics for sex in HAV IgG(þ) c2(overall)Z 2.6575, pZ 0.1031. Calculated
by Cochran-Mantel-Haenszel Statistics for sex in HEV IgG(þ) c2(overall)Z 2.2310, pZ 0.1353. HAVZ hepatitis A virus; HEVZ hepatitis E virus.
A seroprevalence study of hepatitis A and E viruses in Korea 49Likewise, significant differences were also observed
among the 37.00% (among individuals in their 10s),
63.27% (20s), 95.92% (30s), and 100% (40s) prevalence
rates for females (p < 0.01) (Table 3).
No significant difference in the HEV prevalence
was revealed between males and females. However, on
the basis of age, significant differences were observed
between the 1.04% (among individuals in their 10s),
4.26% (20s), 8.16% (30s), and 31.25% (40s) preva-
lence rates for males (p < 0.01). Significant differences
were also observed between the 0.00% (among indi-
viduals in their 10s), 6.12% (20s), 6.12% (30s), and
15.15% (40s) prevalence rates for females (p < 0.01)
(Table 3). Prevalence significantly increased with age
(Table 4).4. Discussion
Our study successfully reports the seroprevalence of
HAV and HEV in Korea on the basis of age, sex and
residency. The overall seroprevalence of HAV among
this population was 63.80% (55.21% and 95.92% for
people aged in their 20s and 30s, respectively; p < 0.01)
and that of HEV was 9.40% (5.21% and 7.14% forTable 4. Seroprevalence of antibodies against HAV/HEV acco
Age groups
Percent positives (number of anti-HAV
IgG positive/total number)
Urban* Suburban* Rura
10e14 43.48 (20/46) 35.94 (23/64) 25.00 (
15e19 20.00 (6/30) 35.14 (13/37) 27.27 (
20e29 50.00 (23/46) 62.22 (28/45) 40.00 (
30e39 93.02 (40/43) 97.96 (48/49) 100.00 (
40e59 100.00 (22/22) 100.00 (30/30) 100.00 (
60 92.86 (13/14) 100.00 (9/9) 100.00 (
Total 61.69 (124/201) 64.53 (151/234) 68.52 (
*A p value <0.0001 by c2 test. Calculated by Cochran-Mantel-Haenszel Stat
Calculated by Cochran-Mantel-Haenszel Statistics for residency in HEV Ig
HEV Z hepatitis E virus.people aged in their 20s and 30s, respectively; p < 0.01)
in the same population. The significantly higher HEV
positive rate in rural areas compared with urban areas
(p < 0.01) might be a consequence of the inferior tap
water and other sanitary facilities available to people
living in rural locations.
HAV was previously endemic in Korea during the
1980s, with most adults acquiring natural immunity
through asymptomatic infection [17,18]. Since 2001,
Korea has experienced a nationwide outbreak of HAV, as
indicated by data from the nationwide surveillance report
for acute hepatitis A by the Korea Centers for Disease
Control and Prevention (www.cdc.go.kr). The number of
annual reported cases of hepatitis A in 2005 was 798,
which increased to 2,081 in 2006 and 2,233 in 2007.
A further abrupt increase in incidence was observed from
2008 (n Z 7,895) to 2009 (n Z 15,231), followed by
a potential decline in 2010 (n Z 6,794 up to October
2010). Since the implementation of improved standards
of hygiene and sanitation in Korea, anti-HAV antibody
prevalence in the 1e20 years of age group declined from
60% in 1980 to 9% in 1995 [19], and the age group of the
most susceptible population has changed from young
children to older children and adults [15,16,19,20]. Given
that clinically severe cases of HAV infection have alsording to age and residency
Percent positives (number of anti-HEV
IgG positive/total number)
l* Urban* Suburban* Rural*
2/8) 0.00 (0/46) 1.56 (1/64) 0.00 (0/8)
3/11) 0.00 (0/30) 0.00 (0/37) 0.00 (0/11)
2/5) 4.35 (2/46) 6.67 (3/45) 0.00 (0/5)
6/6) 9.30 (4/43) 6.12 (3/49) 0.00 (0/6)
13/13) 18.18 (4/22) 16.67 (5/30) 46.15 (6/13)
11/11) 57.14 (8/14) 33.33 (3/9) 63.64 (7/11)
37/54) 8.96 (18/201) 6.41 (15/234) 24.07 (13/54)
istics for residency in HAV IgG(þ) c2(overall) Z 0.2991, p Z 0.5845.
G(þ) c2(overall) Z 0.8436, p Z 0.3584. HAV Z hepatitis A virus;
50 H. Yun, et alrecently increased in Korea, active immunization against
this disease should be considered [20,21].
HEV is one of the causative agents of enterically
transmitted non-A/non-B hepatitis worldwide. It is
responsible for the major outbreaks of acute hepatitis in
developing countries, especially in tropical and
subtropical regions of the world, where outbreaks are
usually associated with fecal contamination of drinking
water [1,3,22]. Although the highest prevalence is found
mostly in countries where the disease is endemic, such
as India, the geographic prevalence of people with ant-
HEV antibodies is worldwide [10,23].
Although Korea is not an endemic area of hepatitis E,
the human HEV genotype III was previously isolated
from Korean population, and also the human HEV
genotype IV, which was first isolated by our research
team [24,25]. Limited cases of acute viral hepatitis E
have been reported, and few studies have been con-
ducted on the epidemiology of this infection in Korea.
Given that the sample size used for our study was
relatively small, our data might not be an accurate
representation of the entire population. However, this
study does provide certain important information con-
cerning the prevalence of HAV and HEV in Korea based
on age, sex, and residency. Furthermore efforts are needed
to clarify the prevalence in the younger generation (i.e.
below 10 years) and the modes of transmission involved.
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